search
Back to results

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

Primary Purpose

Sickle Cell Disease

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
L-citrulline tablets, 1000 mg
Sponsored by
Angiogenix
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sickle Cell Disease focused on measuring sickle cell disease

Eligibility Criteria

10 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values Diagnosis of sickle cell anemia (Hb SS) For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception Has signed and received a copy of the written informed consent form approved by the investigator's Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol Exclusion Criteria: History of sickle-cell-related pain crisis within two weeks of study Pregnant or breast feeding Transfusion within last 90 days Creatinine >1.5 X upper limit of normal SGPT > 2 X upper limit of normal History of allergic reaction to arginine or citrulline product Requires chronic medication other than study drug that cannot be discontinued during the study period Unable to take or tolerate oral medications Unreliable venous access Noncompliant with regular care Participation in an investigational drug or medical device study within previous 30 days In the opinion of the investigator is not a good candidate for participation in the study

Sites / Locations

  • Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Health System

Outcomes

Primary Outcome Measures

PK and PD responses to L-citrulline
Endpoints will be determined as change from baseline

Secondary Outcome Measures

Assessment of safety and tolerability of L-citrulline,

Full Information

First Posted
June 21, 2006
Last Updated
June 21, 2006
Sponsor
Angiogenix
search

1. Study Identification

Unique Protocol Identification Number
NCT00343954
Brief Title
PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
Official Title
Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2006
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Angiogenix

4. Oversight

5. Study Description

Brief Summary
To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.
Detailed Description
Phase 1, single center, open label, multiple-dose study consisting of a screening period followed by four weeks of treatment. At least 12 male and female patients, 10 years of age or older, with sickle cell disease but otherwise healthy, will be enrolled in the study. PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and L-proline following the first dose of orally administered L-citrulline and after four weeks of twice daily administration of the drug. PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of vascular function.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease
Keywords
sickle cell disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
L-citrulline tablets, 1000 mg
Primary Outcome Measure Information:
Title
PK and PD responses to L-citrulline
Title
Endpoints will be determined as change from baseline
Secondary Outcome Measure Information:
Title
Assessment of safety and tolerability of L-citrulline,

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values Diagnosis of sickle cell anemia (Hb SS) For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception Has signed and received a copy of the written informed consent form approved by the investigator's Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol Exclusion Criteria: History of sickle-cell-related pain crisis within two weeks of study Pregnant or breast feeding Transfusion within last 90 days Creatinine >1.5 X upper limit of normal SGPT > 2 X upper limit of normal History of allergic reaction to arginine or citrulline product Requires chronic medication other than study drug that cannot be discontinued during the study period Unable to take or tolerate oral medications Unreliable venous access Noncompliant with regular care Participation in an investigational drug or medical device study within previous 30 days In the opinion of the investigator is not a good candidate for participation in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lakshmanam Krishnamurti, MD
Organizational Affiliation
Children's Hospital of Pittsburgh, Univ. of Pittsburgh Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Health System
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lakshmanan Krishnamurti, MD
Phone
412-692-7192
First Name & Middle Initial & Last Name & Degree
Sidney Morris, PhD
Phone
(412) 648-9338

12. IPD Sharing Statement

Learn more about this trial

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

We'll reach out to this number within 24 hrs